Clinical trial · Interventional
Feasibility of Multi-cancer Early Detection Test in Screening Population (NQMD-CS)
NQMD-CS: A Prospective Interventional Study to Evaluate the Feasibility of a Blood-Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
This is a prospective, multicenter screening cohort study designed to evaluate the feasibility of a blood-based multi-cancer early detection (MCED) test in an asymptomatic screening population. Eligible participants will undergo blood-based MCED testing, standard cancer screening as appropriate, and 1-year active follow-up. Participants with positive MCED results or highly suspicious findings from standard screening will undergo diagnostic evaluation to determine cancer status, enabling a more accurate assessment of the test's clinical performance.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Grastic Cancer | — | UNRESOLVED | — |
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MCED | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- MCED-screening
- description
- MCED results are returned to investigators and participants. Participants with a cancer signal undergo clinician-guided diagnostic assessment to confirm or rule out cancer
- interventionNames
- Diagnostic Test: MCED
Primary outcomes (2)
- measure
- Feasibility of MCED in the intended use setting
- timeFrame
- From enrollment to the Follow-up at 1 year
- description
- Descriptive statistics will be used to summarize the number of the five pre-specified cancers diagnosed by MCED.
- measure
- Safety of MCED in the intended use setting
- timeFrame
- From enrollment to the Follow-up at 1 year
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 74 Years
Show eligibility criteria text
Inclusion Criteria: 1.40-74 years old; 2.Able to provide a written informed consent; 3.Willing to comply with all part of the protocol procedures. Exclusion Criteria: 1. With cancer-associated clinical symptoms or suspected of cancer within 30 days prior to screen; 2. Have definite contraindications of cancer screening examination and diagnostic procedures; 3. Unable to comply with the protocol procedures; 4. Personal history of cancer, diagnosed within the 3 years prior to expected enrollment date; 5. Have received or are undergoing curative cancer treatment within three years prior to recruitment. Adjuvant endocrine therapy for cancer is not an exclusion criterion; 6. Recipients of anti-tumor therapy within 30 days prior to screen; 7. Pregnancy or lactating women; 8. Recipients of organ transplant or prior bone marrow transplant or stem cell transplant; 9. Recipients of blood transfusion within 7 days prior to screen; 10. With autoimmune diseases; 11. Have an acute infection or inflammation or uncontrolled chronic infection within 14 days prior to blood draw; 12. Unsuitable for this trial determined by the researchers.
References
Publications (0)
Data not yet available